Navigation Links
A new disease: couch potato: needs drug therapy

Couch potato is a layman word for “Extreme laziness” which is a medical condition called motivational deficiency disorder (MoDeD). This was told by Australian researchers in a report in the 1 April issue of the British Medical Journal (BMJ) // Professor Leth Argos, a neuroscientist at the University of Newcastle, reportedly identified the new disorder.

In severe cases it can be fatal because the condition reduces the motivation to breathe, his report adds. It's diagnosed using a combination of positron emission tomography and low scores on a motivation rating scale, previously validated in elite athletes. Drug therapy involves treatment by various drugs.

An Australian biotechnology company called Healthtec, advised by Argos, has had promising trial results of the new drug indolebant, and designed to help people with the condition, as Moynihan "One young man who could not leave his sofa is now working as an investment adviser in Sydney."

Professor David Henry of the University of Newcastle says, “While some extreme sufferers of MoDeD may benefit from indolebant, common laziness is not a disease. Some people might have a genuinely debilitating form of MoDeD but others are just plain lazy and have "an absolute right to just sit there.”

Moynihan is critical of the role of Healthtec's promotion of MoDeD and what he calls the “corporate-sponsored creation of illness".

Moynihan says, “In almost any condition you take there are people at the severe end of the spectrum who benefit greatly from a medical label and from therapy including medication. I think that people who react negatively to this debate about disease mongering do a disservice to the genuinely ill."

'"/>




Page: 1

Related medicine news :

1. Stem cell cure for peripheral vascular disease: New hope on the horizon
2. Heart disease: Men Are From Mars, Women From Venus
3. Another dietary medicine for Alzheimer’s disease: Red cabbage
4. A potato (couch or not) in the diet adverse for diabetics.
5. Couch potato parents make couch potato kids!
6. Body mass index guide needs revision
7. Risk of heart disease prediction needs updating
8. Air pollution combined with greater medical needs
9. Treatment of postpartum depression needs to be personalized
10. FDA needs to be more vigilant in monitoring, tissue banks.
11. Australia: Salt needs More of Iodine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From ... the year’s best in pioneering, inventive, and ultimately successful projects undertaken by the ...
(Date:12/7/2016)... ... ... "ProBrand Flip allows FCPX editors to create unique logo reveals which can ... Film Studios. , ProBrand Flip includes 30 flip book reveal animations. Easily reveal any ... variety of flip book animations. In Addition, users can modify each preset to fit ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... WellnessPro Plus for consumers and healthcare professionals to manage chronic and acute ... the treatment modalities available in a single device. The announcement is part ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: an ... not a one hour a week showing of hands. “The Road To Restoration” is ... “Perhaps you are familiar with the brass ring that you could reach out for, ...
(Date:12/7/2016)... ... ... “Walking With God: Inspirational Lessons from My Life's Journey”: a sometimes serious, ... God's direction in their lives. “Walking With God: Inspirational Lessons from My Life's Journey” ... , Sanford says, “I enjoy sharing the true stories in my book ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
Breaking Medicine Technology: